Request Demo
Last update 29 Apr 2026
QLS2309
Last update 29 Apr 2026
Overview
Basic Info
Drug Type Bispecific killer cell engager (BiKE) |
Synonyms QLS2309 |
Target |
Action antagonists, inhibitors |
Mechanism CD16a antagonists(Low affinity immunoglobulin gamma Fc region receptor III-A antagonists), CD70 inhibitors(CD70 antigen inhibitors), NKp46 inhibitors(Natural cytotoxicity triggering receptor 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with QLS2309NCT07173595
A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
100 Clinical Results associated with QLS2309
Login to view more data
100 Translational Medicine associated with QLS2309
Login to view more data
100 Patents (Medical) associated with QLS2309
Login to view more data
100 Deals associated with QLS2309
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hematologic Neoplasms | Phase 1 | China | 05 Dec 2025 | |
| Acute Myeloid Leukemia | Preclinical | China | 27 Apr 2026 | |
| Lymphoma | Preclinical | China | 27 Apr 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free